Previous 10 | Next 10 |
Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment. Oncology companies get ready to present new data at the largest US oncology conference with potential fo...
Berwyn, Pennsylvania--(Newsfile Corp. - June 1, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the notable finding that in a test tha...
Berwyn, Pennsylvania--(Newsfile Corp. - May 28, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the engageme...
Berwyn, Pennsylvania--(Newsfile Corp. - May 27, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the closing o...
In the short term at least, ANVS401 appears to improve cognition in Alzheimer's patients, and speed, coordination, and motor skills in Parkinson's patients. The drug may do so in part by lowering levels of the amyloid precursor protein and alpha-synuclein, respectively. ANVS401's ...
Annovis Bio tripled Friday after reporting exciting Alzheimer's data. Its drug posiphen is not clearing plaques or flooding receptors, but inhibits amyloid-β precursor protein from translating toxic Aβ. Posiphen looks promising in Alzheimer's, Parkinson's, Downs, and...
Creative Realities (CREX) +34%.Virgin Galactic Holdings (SPCE) +19% after successful weekend space flight.Strongbridge Biopharma (SBBP) +15% after being acquired by Xeris Pharma.Jiuzi Holdings (JZXN) +9%.Aptorum Group Limited (APM) +9% on positive interim phase I clinical trial...
Annovis Bio (ANVS) has priced its public offering of 1M common shares at $50.00/share, for gross proceeds of $50M. Net proceeds will be used for general corporate purposes, including working capital, R&D and the completion of Phase 3 ANVS401 trail in Alzheimer's disease in perso...
Berwyn, Pennsylvania--(Newsfile Corp. - May 23, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the pricing o...
On May 21, ANVS doubled on phase 2 data for improved cognition in Alzheimer's disease. The stock has increased more than 600% since my first coverage this January. Previously, ANVS reported ANVS-401 improved speed, coordination, motor function and significantly lowered inflammator...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...